Fulgent Genetics Projects Significant 2026 Non-GAAP Loss Due to Major Customer Departure

summarizeSummary

Fulgent Genetics reported Q4 and full-year 2025 results, but issued a significantly negative 2026 outlook, projecting a substantial non-GAAP loss due to its largest customer moving work in-house, despite positive clinical pipeline updates.

check_boxKey Events

• Q4 & FY 2025 Results

  Reported Q4 revenue of $83.3 million (up 9% year-over-year) and full-year revenue of $322.7 million (up 14% year-over-year), with a GAAP loss of ($0.76) per share in Q4 and ($1.97) for the full year.

• Negative 2026 Guidance

  Projected 2026 non-GAAP loss of approximately ($1.45) per share, a significant decline from 2025's non-GAAP income of $0.42 per share.

• Major Customer Loss

  The negative 2026 outlook is primarily driven by the company's largest customer moving a significant volume of work in-house, impacting future revenue.

• Strong Cash Position

  Ended 2025 with $705.5 million in cash, cash equivalents, and marketable securities, providing financial stability and runway.

auto_awesomeAnalysis

Fulgent Genetics' latest financial report presents a mixed picture, with solid 2025 revenue growth overshadowed by a concerning 2026 outlook. The company projects a significant non-GAAP loss per share for 2026, a sharp reversal from 2025's non-GAAP income. This deterioration is primarily attributed to its largest customer internalizing a substantial volume of work, indicating a material business challenge. While the company maintains a strong cash position and reported promising preliminary Phase 2 clinical data for FID-007 in Head & Neck cancer, the near-term financial headwinds from the customer loss are substantial and will likely be a key focus for investors. The company aims for acquisitions to partially offset this impact in the second half of 2026.